Skip to main content

Table 1 Baseline clinical characteristics and data for patients with IPF and patients with CPFE-UIP

From: Prognosis of patients with acute exacerbation of combined pulmonary fibrosis and emphysema: a retrospective single-centre study

Parameter

Patients with IPF (n = 41)

Patients with CPFE (n = 21)

p-value

Sex

 Male/Female

34/7 (83%/17%)

19/2 (91%/9%)

0.676

Age (y)

71 (67–75)

74 (69–76)

0.14

Cigarette smoking (pack-years)

32 (0.875–44.75) (n = 38)

51(29.5–69) (n = 19)

0.0058

Patients using corticosteroid drugs

8 (19.5%)

6 (28.6%)

0.419

Patients using immunosuppressant drugs

1 (2%)

1 (4.8%)

0.788

Patients using antifibrotic drugs (e.g. pirfenidone or nintedanib)

10 (24.4%)

3 (14.3%)

0.552

Patients receiving NAC inhalation

1 (0.2%)

0(0%)

0.73

Patients receiving supplemental oxygen

12 (29.3%)

9 (42.9%)

0.285

LAA score (points)

1 (0–3)

10 (9–15)

< 0.001

%FVC (%)

64.5 (53.2–80.9) (n = 28)

79.3 (73.7–90.1) (n = 17)

0.0069

%DLco (%)

39.8 (29.8–51.9) (n = 21)

35.4 (30.6–41.1) (n = 14)

0.2461

FEV1 / FVC

84.75(83–88.4)

81.2(72.3–87.5)

0.018

GAP score (points)

4.5 (4–6) (n = 22)

4.5 (4–5) (n = 14)

0.58

CPI

55.4 (45.4–61.8) (n = 22)

52.6 (46.3–58.0) (n = 14)

0.41

P/F ratio (Torr)

331 (291–358) (n = 26)

328 (315–366) (n = 17)

0.555

TR-PG (mmHg)

22.3 (15.5–31.2) (n = 15)

22.6 (18.1–26.1) (n = 6)

0.969

WBC count (/mm3)

7805 (6575–8337.5) (n = 33)

6780 (6270–8000) (n = 20)

0.238

CRP (mg/dL)

0.14 (0.06–0.26) (n = 29)

0.11 (0.04–0.26) (n = 19)

0.51

LDH (IU/L)

222 (201–267) (n = 29)

234 (207–252) (n = 19)

0.78

KL-6 (U/mL)

1246 (899–1494) (n = 33)

636.5 (442–1102) (n = 19)

0.004

RF (IU/mL) < 10 /≥10

25/11 (n = 36) a

9/8 (n = 17)b

0.242

ANA < 1:40 / ≥1:40

20/15 (n = 35) c

9/9 (n = 18) d

0.621

  1. The parameters are expressed as number (percentage) or median (interquartile range). For insufficient data, the confirmed numbers are indicated by ‘n =’
  2. IPF idiopathic pulmonary fibrosis, CPFE combined pulmonary fibrosis and emphysema, UIP usual interstitial pneumonia, NAC n-acetyl-cysteine, LAA low attenuation area, %FVC percent predicted forced vital capacity, %DLco diffusing capacity for carbon monoxide, FEV1/FVC forced expiratory volume in 1 s /forced volume vital capacity ratio, GAP Gender-Age-Physiology, CPI composite physiologic index, P/F ratio of partial pressure arterial oxygen to fraction of inspired oxygen (PaO2/FiO2, TR-PG transtricuspid pressure gradient, WBC white blood cell, CRP C-reactive protein, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, RF rheumatoid factor, ANA anti-nuclear antibodies
  3. a14 out of 36 patients were data at acute exacerbation. b 8 out of 17 patients were data at acute exacerbation. c 13 out of 35 patients were data at acute exacerbation. d10 out of 18 patients were data at acute exacerbation